104 completed, 20 recruiting, 12 unknown, 8 active not recruiting. 163 Phase 2, 40 Phase 1, 19 Phase 3.
Follow Type 1 Diabetes: new trials by email Literature Review of Type 1 Diabetes trials Research Report on Type 1 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Verapamil In Preclinical Type 1 Diabetes Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release, Placebo, blood sampling - Type 1 Diabetes | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2027-01-01 | 2026-10-22 |
| Precision T1D Platform - New Therapies for Cardio-Renal Complications Finerenone, Sotagliflozin - Type 1 Diabetes, T1D Heart Failure | Phase 2 | Not yet recruiting | Oregon Health and Science University | 57 | 2026-11-01 | 2026-08-10 |
| Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Semaglutide, Placebo - Type 1 Diabetes, Overweight , Obesity | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 40 | 2026-10-13 | 2026-10-23 |
| Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT) - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Not yet recruiting | AdventHealth Translational Research Institute | 75 | 2026-06-01 | 2026-02-19 |
| A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar Tirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Carbohydrate Counting - Type 1 Diabetes, Type 1 Diabetes Mellitus | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 105 | 2026-05-19 | 2026-05-27 |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab - Type 1 Diabetes, New Onset | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 120 | 2026-03-10 | 2026-10-16 |
| Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus Sorafenib, Placebo - Type 1 Diabetes | Phase 2 | Not yet recruiting | Second Xiangya Hospital of Central South University | 10 | 2026-02-01 | 2026-02-12 |
| The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation Colchicin 0.5 mg once daily for two weeks, then twice daily for two weeks, Placebo once daily for two weeks, then twice daily for two weeks, Colchicine tablet 0.5 mg once-daily for two weeks, then twice daily for two weeks - Type 1 Diabetes, Chronic Inflammation | Phase 2 | Recruiting | Asger Lund, MD | 26 | 2025-12-01 | 2025-12-23 |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes High Dose SAB-142, Low Dose SAB-142, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | SAb Biotherapeutics, Inc. | 159 | 2025-11-25 | 2026-10-13 |
| Precision Administration of Anti-thymocyte Globulin With or Without Verapamil Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | University of Florida | 60 | 2025-11-12 | 2025-11-26 |
| The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes Liraglutide Pen Injector, Saline Injections - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-10-03 | 2026-10-19 |
| A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil Verapamil (Part A), Placebo - Type 1 Diabetes | Phase 1 / Phase 2 | Recruiting | Johnny Ludvigsson | 36 | 2025-08-06 | 2025-09-30 |
| A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus OPF-310 - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Recruiting | Otsuka Pharmaceutical Factory, Inc. | 13 | 2025-06-10 | 2026-08-21 |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) CNP-103, Placebo - Type 1 Diabetes Mellitus, T1D | Phase 1 / Phase 2 | Recruiting | COUR Pharmaceutical Development Company, Inc. | 72 | 2025-05-12 | 2026-09-11 |
| Denosumab for Type 1 Diabetes Denosumab, Placebo - Type 1 Diabetes | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 45 | 2025-05-05 | 2026-10-20 |
| Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes Lyumjev 100 UNT/ML Injectable Solution, Premixed Lyumjev - Type 1 Diabetes | Phase 1 / Phase 2 | Terminated | St. Olavs Hospital | 9 | 2025-04-01 | 2026-10-19 |
| Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes Insulin producing stem cells infusion - Stem Cells, Type 1 Diabetes | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 20 | 2025-04-01 | 2025-04-30 |
| Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes Sotagliflozin, Placebo - Type 1 Diabetes, Heart Failure | Phase 2 | Recruiting | University of Dundee | 320 | 2025-01-28 | 2026-04-06 |
| Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide Semaglutide with 4 meal strategies, Placebo with 4 meal strategies - Type 1 Diabetes, Diabetes Mellitus | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 26 | 2024-12-01 | 2024-12-18 |
| SGLT2 Adjunct in T1D Empagliflozin (EMPA), Placebo - Type 1 Diabetes, Nephropathy, Diabetic | Phase 2 / Phase 3 | Completed | Ain Shams University | 86 | 2024-11-20 | 2026-05-18 |
Showing 20 of 163. Sign in to see all of them.
Diabetes Mellitus, Type 1 (163) · Hypoglycemia (32) · Insulin Resistance (27) · Diabetes Mellitus (21) · Autoimmune Diseases (4) · Obesity (3) · Diabetes Mellitus, Type 2 (2) · Diabetic Nephropathies (2) · Heart Failure (2) · Hyperglycemia (2) · Inflammation (2) · Kidney Diseases (2) · Metabolic Diseases (2) · Overweight (2) · Pain (2)
Endocrine System Diseases (163) · Nutritional and Metabolic Diseases (163) · Glucose Metabolism Disorders (162) · Immune System Diseases (162) · Metabolic Diseases (161) · Autoimmune Diseases (159) · Diabetes Mellitus (142) · Hyperinsulinism (27) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (7) · Body Weight (4) · Nutrition Disorders (4) · Overnutrition (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3)
Insulin (17) · Liraglutide (9) · Glucagon (8) · Methods (7) · Insulin Infusion Systems (5) · Sitagliptin Phosphate (5) · Sodium Chloride (5) · thymoglobulin (5) · (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (4) · Antilymphocyte Serum (4) · Continuous Glucose Monitoring (4) · Insulin Aspart (4) · Sirolimus (4) · semaglutide (4) · Abatacept (3)
Institut de Recherches Cliniques de Montreal (18) · Assistance Publique - Hôpitaux de Paris (6) · University of Minnesota (6) · McGill University Health Centre/Research Institute of the McGill University Health Centre (5) · University of California, San Diego (5) · University of Cambridge (5) · Jaeb Center for Health Research (4) · Massachusetts General Hospital (4) · University of Alberta (4) · Hvidovre University Hospital (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Steno Diabetes Center Copenhagen (3) · University of Oulu (3) · Ain Shams University (2) · Asger Lund, MD (2)
United States (67) · Canada (36) · United Kingdom (12) · France (11) · Denmark (8) · Italy (8) · Sweden (7) · Germany (6) · Switzerland (6) · Australia (5) · Belgium (4) · China (4) · Finland (4) · Netherlands (4) · Austria (3)
Roman Hovorka, PhD (5) · John Lum, MS (3) · Remi Rabasa-Lhoret (3) · Riitta Veijola, MD (3) · A.M. James Shapiro, MD, PhD (2) · Bernhard J. Hering, M.D. (2) · Bruce A Buckingham, MD (2) · Christian Laugesen, MD (2) · Elizabeth R Seaquist, MD (2) · Lorenzo Piemonti, MD (2) · Melissa-Rosina Pasqua, MD, PhD (2) · Rodica Pop-Busui, MD, PhD (2)
PMID 35797241, PMID 23438305, PMID 23562090, PMID 24432999, PMID 26241693, PMID 34091488, PMID 10024506, PMID 10433086, PMID 10605821, PMID 10752702, PMID 10852253, PMID 11208527, PMID 11564949, PMID 11815483, PMID 12176626, PMID 12176628, PMID 12972423, PMID 14961992, PMID 15233820, PMID 15713772, PMID 15972654, PMID 16011702, PMID 16714282, PMID 17214730, PMID 1730582, PMID 17524725, PMID 18176934, PMID 18360702, PMID 18843118, PMID 19073764, PMID 19188144, PMID 19366957, PMID 19571282, PMID 19689275, PMID 19763038, PMID 19968980, PMID 19997760, PMID 20127992, PMID 20142543, PMID 20332358, PMID 20357369, PMID 20405312, PMID 20501948, PMID 20956533, PMID 21084848, PMID 21116604, PMID 21147316, PMID 21389784, PMID 21636800, PMID 21715517
2014 (4), 2025 (3), R01DK085591 (3), UC4DK106993 (2), UC4DK117009 (2), 2023 (1), K23DK129799 (1), R01DK062440 (1), R01DK119246 (1), R01DK127491 (1), R21DK113353 (1), UC4DK097835 (1), UL1TR001082 (1)